SFDA Penalizes Drug Companies For Monopoly
This article was originally published in PharmAsia News
Executive Summary
China’s National Development and Reform Commission recently imposed fines of RMB 6.877 million and RMB 152,600 on two drug companies for attempts to monopolize the markets.